DOCSLIB.ORG

Pimavanserin Tartrate: a 5-HT2A Inverse Agonist with Potential for Treating Various 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pimavanserin Tartrate: a 5-HT2A Inverse Agonist with Potential for Treating Various 1 Drug Evaluation Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various 1. Introduction neuropsychiatric disorders 2. Schizophrenia † 3. Psychosis in Parkinson’s disease Atheir Abbas & Bryan L Roth † National Institute of Mental Health Psychoactive Drug Screening Program, 4. 5-HT2A antagonists/inverse University of North Carolina, Lineberger Cancer Center, Medicinal Chemistry, Psychiatry, agonists and sleep Pharmacology, Chapel Hill, NC 27516, USA 5. Chemistry 6. Pharmacodynamics Background : Pimavanserin tartrate is the first 5-HT 2A inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson’s 7. Pharmacokinetics disease and for augmentation of low-dose risperidone treatment in schizo- 8. Clinical effi cacy (see Table 1 phrenia. Pimavanserin is also being evaluated as a possible anti-insomnia for concise summary) drug. Objective : To discuss the potential of pimavanserin to fill multiple 9. Safety and tolerability therapeutic needs. Methods : The problems with currently approved antipsy- 10. Conclusions chotics and sleep agents are explored to highlight how pimavanserin might 11. Expert opinion address some longstanding issues in the treatment of psychosis and insomnia. Results/conclusions : In Phase II clinical trials, pimavanserin seemed to be safe, well-tolerated and efficacious in treating L -dopa-induced psychosis without worsening motor symptoms. Pimavanserin also potentiated the therapeutic effects of low-dose risperidone, reduced haloperidol-induced akathisia, and increased slow-wave sleep in older individuals. Keywords: 5-HT2A , 5-HT2A , antipsychotic , inverse agonist , Parkinson’s Disease , pimavanserin , For personal use only. psychosis , schizophrenia Expert Opin. Pharmacother. (2008) 9(18):3251-3259 1. Introduction Pimavanserin tartrate (ACP-103, Acadia Pharmaceuticals, Sorrento Valley, CA) is a 5-HT2A inverse agonist in clinical trials for the treatment of psychosis in Parkinson’s disease (PD) and as adjunct therapy in the treatment of schizophrenia. 2. Schizophrenia The disease most often associated with psychosis is schizophrenia, a debilitating Expert Opin. Pharmacother. Downloaded from informahealthcare.com by University of Louisville on 09/30/13 psychiatric illness whose etiology remains largely unknown, though some form of glutamatergic dysfunction is thought to underlie the disease [1] . Schizophrenia has been estimated to have an annual incidence of between 2 and 4 per 10,000, with a prevalence 10 times that rate [2] . Schizophrenia is characterized by deficits in three symptom domains: positive, negative, and cognitive (see reference [3] for more details). To date, all approved drug therapies are most effective in treating positive symptoms, with moderate efficacy in treating negative and cognitive symptoms [3] . This relative lack of efficacy for treating negative and cognitive symptoms of schizophrenia is unfortunate, as the severity of negative symptoms is the best predictor of quality of life, and severity of cognitive dysfunction is positively correlated with functional outcome in patients with schizophrenia [3] . The economic impact of schizophrenia is large and growing rapidly – from an estimated $32.5 billion in 1990 [2] to $63 billion just 12 years later [4] . A 10.1517/14656560802532707 © 2008 Informa UK Ltd ISSN 1465-6566 3251 All rights reserved: reproduction in whole or in part not permitted Pimavanserin tartrate substantial portion of the cost of schizophrenia is due to more useful in treating unrelated symptom domains of one indirect costs – resulting from increased mortality and illness [6] . Alternatively, polypharmacy using more selective morbidity, criminal behavior, use of social welfare programs, agents aimed at treating the different symptom domains and family caregiving costs [5] . By some estimates, these individually could achieve similar results [3] . indirect costs represent half or more of the economic cost of A major issue in the treatment of schizophrenia is the fact schizophrenia, with direct costs – money spent on drug that the antipsychotic treatments are characterized by high treatment and hospitalizations, for example – accounting rates of patient non-compliance. A survey of 24 different for the other half [2,5] . studies of varying sample sizes estimated patient compliance The pharmacotherapy of schizophrenia began more than in taking antipsychotic medications as prescribed to range 50 years ago with the discovery of chlorpromazine, the first from 24 to 90%, with an average of 58% [21] . In the antipsychotic used to treat the disease [3] . The earlier genera- most rigorous studies, in which urine tests were accompanied tions of antipsychotics were effective in treating the more by pill counts, the average rate of compliance was 60% [21] . salient symptoms exhibited by schizophrenic patients such as The economic cost of non-compliance is likely to represent hallucinations and delusions [6] . These first generation anti- a significant portion of the societal cost of schizophrenia. psychotics are now referred to as typical antipsychotics and For example, rehospitalization costs due to non-compliance are characterized primarily by high affinity for D2 dopamine with prescribed medication regimens by Medicaid patients receptors and a number of class-specific side effects [6] . The alone were estimated to be almost $1.5 billion, and possibly class-specific side effects include extrapyramidal symptoms higher [4] . Increased mortality and morbidity in non-compliant (EPS), which refer to the various movement disorders that patients, along with an increased burden on community can result from typical antipsychotic treatment – tardive resources and family caregivers, are likely to increase the dyskinesia, akathisia and dystonia. Other class-specific side economic cost to many billions of dollars per year. effects include elevation of serum prolactin and neuroleptic One of the major sources of non-compliance is the highly malignant syndrome (NLS) [6] . unpleasant side-effect profile of both typical and atypical Decades after its initial discovery in 1958, clozapine was antipsychotics [22,23] . As might be expected, drugs with shown to be characterized by a low affinity for D2 receptors different side-effect profiles have different rates of non- and a high affinity for 5-HT2A receptors [7-9] ; a complex compliance and associated direct costs [22]. EPS are unpleasant pharmacological profile [6,8,10,11] ; a lack of EPS [12,13] ; and for obvious reasons, and elevation of serum prolactin can an inability to elevate serum prolactin [3] . The discovery of lead to numerous sexual side effects, which can be among clozapine inspired the development of the next generation the most unpleasant side effects of antipsychotic treatment [24,25] . For personal use only. of antipsychotics, the atypical antipsychotics, which are It was hoped that the newer generation atypical antipsychotics considered ‘atypical’ owing to their reduced EPS and serum would improve patient compliance, but most studies that prolactin elevation liabilities. Many, but not all [14] , atypical compare typicals and atypicals with respect to patient antipsychotic drugs are characterized by a relatively low D2 compliance did not detect any difference [17,23] . This is occupancy at therapeutic doses [15] , and this seems to distinguish probably due to their own unique side effects – for example, them from many typical antipsychotic drugs. Unfortunately, the vast majority of patients experiencing weight gain, a some, but not all, atypical antipsychotics carry their own side effect of many of the atypicals, reported that to be unique side-effect profile, including weight gain and problematic [16,26] . Clearly, new treatments that accelerate metabolic syndrome [3,16] . Furthermore, with the exception symptom reduction, treat multiple symptom domains or of clozapine, atypical antipsychotics are not superior to the improve the side-effect profile of approved agents may increase typicals in their efficacy in most schizophrenic populations [17] , patient compliance (and thus long-term effectiveness of although clozapine has demonstrated utility in diminishing treatment) and improve quality of life. Expert Opin. Pharmacother. Downloaded from informahealthcare.com by University of Louisville on 09/30/13 suicidality [18] and in treatment-resistant schizophrenia [19,20] . It has been proposed that schizophrenia should be sub- 3. Psychosis in Parkinson’s disease divided into the different symptom domains of which it is composed, and it follows that the different symptom domains Parkinson’s disease (PD) is the second most common probably correspond to different therapeutic targets that neurodegenerative disorder after Alzheimer’s disease, with a may have to be treated separately. This may explain why prevalence of 0.3% in industrialized nations and an incidence developing a rapid onset agent with efficacy in treating the of 4 – 20 per 100,000 [27] . Like schizophrenia, the economic positive, negative, and cognitive symptoms of schizophrenia burden of PD is high – a study comparing 20,000 PD has proved so elusive. Novel approaches aimed at developing patients to controls produced an estimated cost of $23 billion effective therapies for schizophrenia have moved away from annually using data from 2002 [28] . Another study showed the predominant paradigm of designing selective drugs – that PD is associated with large direct economic costs ‘magic bullets’ – which appear
Load more

Recommended publications
  • Serotonin 2A Activation and a Novel Therapeutic Drug
    Psychopharmacology (2018) 235:3083–3091 https://doi.org/10.1007/s00213-018-5042-1 THEORETICAL AND METHODOLOGICAL PERSPECTIVE The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug Baland Jalal1 Received: 23 April 2018 /Accepted: 17 September 2018 /Published online: 5 October 2018 # The Author(s) 2018 Abstract Sleep paralysis is a state of involuntary immobility occurring at sleep onset or offset, often accompanied by uncanny Bghost-like^ hallucinations and extreme fear reactions. I provide here a neuropharmacological account for these hallucinatory experiences by evoking the role of the serotonin 2A receptor (5-HT2AR). Research has shown that 5-HT2AR activation can induce visual hallucinations, Bmystical^ subjective states, and out-of-body experiences (OBEs), and modulate fear circuits. Hallucinatory experiences triggered by serotonin—serotonergic (Bpseudo^) hallucinations, induced by hallucinogenic drugs—tend to be Bdream-like^ with the experiencer having insight (Bmeta-awareness^) that he is hallucinating, unlike dopaminergic (Bpsychotic^ and Blife-like^) hallucinations where such insight is lost. Indeed, hallucinatory experiences during sleep paralysis have the classic features of serotonergic hallucinations, and are strikingly similar to perceptual and subjective states induced by hallucinogenic drugs (e.g., lysergic acid diethylamide [LSD] and psilocybin), i.e., they entail visual hallucinations, mystical experiences, OBEs, and extreme fear reactions. I propose a possible mechanism whereby serotonin could be functionally implicated in generating sleep paralysis hallucinations and fear reactions through 5-HT2AR activity. Moreover, I speculate on the role of 5-HT2C receptors vis-à-vis anxiety and panic during sleep paralysis, and the orbitofrontal cortex—rich with 5-HT2A receptors—in influencing visual pathways during sleep paralysis, and, in effect, hallucinations.
    [Show full text]
  • Atypical Antipsychotics TCO 02.2018
    Therapeutic Class Overview Atypical Antipsychotics INTRODUCTION • Antipsychotic medications have been used for over 50 years to treat schizophrenia and a variety of other psychiatric disorders (Miyamato et al 2005). • Antipsychotic medications generally exert their effect in part by blocking dopamine (D)-2 receptors (Jibson et al 2017). • Antipsychotics are divided into 2 distinct classes based on their affinity for D2 and other neuroreceptors: typical antipsychotics, also called first-generation antipsychotics (FGAs), and atypical antipsychotics, also called second- generation antipsychotics (SGAs) (Miyamato et al 2005). • Atypical antipsychotics do not have a uniform pharmacology or mechanism of action; these differences likely account for the different safety and tolerability profiles of these agents (Clinical Pharmacology 2020, Jibson et al 2017). The atypical antipsychotics differ from the early antipsychotics in that they have affinity for the serotonin 5-HT2 receptor in addition to D2. Clozapine is an antagonist at all dopamine receptors (D1-5), with lower affinity for D1 and D2 receptors and high affinity for D4 receptors. Aripiprazole and brexpiprazole act as partial agonists at the D2 receptor, functioning as an ○ agonist when synaptic dopamine levels are low and as an antagonist when they are high. Cariprazine is a partial agonist at D2 and D3. Pimavanserin does not have dopamine blocking activity and is primarily an inverse agonist at 5-HT2A receptors. The remaining atypical antipsychotics share the similarity of D2 and 5-HT2A
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates Et Al
    US008598119B2 (12) United States Patent (10) Patent No.: US 8.598,119 B2 Mates et al. (45) Date of Patent: Dec. 3, 2013 (54) METHODS AND COMPOSITIONS FOR AOIN 43/00 (2006.01) SLEEP DSORDERS AND OTHER AOIN 43/46 (2006.01) DSORDERS AOIN 43/62 (2006.01) AOIN 43/58 (2006.01) (75) Inventors: Sharon Mates, New York, NY (US); AOIN 43/60 (2006.01) Allen Fienberg, New York, NY (US); (52) U.S. Cl. Lawrence Wennogle, New York, NY USPC .......... 514/114: 514/171; 514/217: 514/220; (US) 514/229.5: 514/250 (58) Field of Classification Search (73) Assignee: Intra-Cellular Therapies, Inc. NY (US) None See application file for complete search history. (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 (56) References Cited U.S.C. 154(b) by 215 days. U.S. PATENT DOCUMENTS (21) Appl. No.: 12/994,560 6,552,017 B1 4/2003 Robichaud et al. 2007/0203120 A1 8, 2007 McDevitt et al. (22) PCT Filed: May 27, 2009 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O09/OO3261 S371 (c)(1), WO WOOOf77OO2 * 6, 2000 (2), (4) Date: Nov. 24, 2010 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2009/145900 Rye (Sleep Disorders and Parkinson's Disease, 2000, accessed online http://www.waparkinsons.org/edu research/articles/Sleep PCT Pub. Date: Dec. 3, 2009 Disorders.html), 2 pages.* Alvir et al. Clozapine-Induced Agranulocytosis. The New England (65) Prior Publication Data Journal of Medicine, 1993, vol. 329, No. 3, pp. 162-167.* US 2011/0071080 A1 Mar.
    [Show full text]
  • Reviews Insights Into Pathophysiology from Medication-Induced Tremor
    Freely available online Reviews Insights into Pathophysiology from Medication-induced Tremor 1* 1 1 1 John C. Morgan , Julie A. Kurek , Jennie L. Davis & Kapil D. Sethi 1 Movement Disorders Program Parkinson’s Foundation Center of Excellence, Department of Neurology, Medical College of Georgia, Augusta, GA, USA Abstract Background: Medication-induced tremor (MIT) is common in clinical practice and there are many medications/drugs that can cause or exacerbate tremors. MIT typically occurs by enhancement of physiological tremor (EPT), but not all drugs cause tremor in this way. In this manuscript, we review how some common examples of MIT have informed us about the pathophysiology of tremor. Methods: We performed a PubMed literature search for published articles dealing with MIT and attempted to identify articles that especially dealt with the medication’s mechanism of inducing tremor. Results: There is a paucity of literature that deals with the mechanisms of MIT, with most manuscripts only describing the frequency and clinical settings where MIT is observed. That being said, MIT emanates from multiple mechanisms depending on the drug and it often takes an individualized approach to manage MIT in a given patient. Discussion: MIT has provided some insight into the mechanisms of tremors we see in clinical practice. The exact mechanism of MIT is unknown for most medications that cause tremor, but it is assumed that in most cases physiological tremor is influenced by these medications. Some medications (epinephrine) that cause EPT likely lead to tremor by peripheral mechanisms in the muscle (b-adrenergic agonists), but others may influence the central component (amitriptyline).
    [Show full text]
  • Low Continuation of Antipsychotic Therapy in Parkinson Disease – Intolerance, Ineffectiveness, Or Inertia? Thanh Phuong Pham Nguyen1,2,3,4*, Danielle S
    Pham Nguyen et al. BMC Neurology (2021) 21:240 https://doi.org/10.1186/s12883-021-02265-x RESEARCH Open Access Low continuation of antipsychotic therapy in Parkinson disease – intolerance, ineffectiveness, or inertia? Thanh Phuong Pham Nguyen1,2,3,4*, Danielle S. Abraham1,2,3,4, Dylan Thibault1,2, Daniel Weintraub1,5 and Allison W. Willis1,2,3,4,6 Abstract Background: Antipsychotics are used in Parkinson disease (PD) to treat psychosis, mood, and behavioral disturbances. Commonly used antipsychotics differ substantially in their potential to worsen motor symptoms through dopaminergic receptor blockade. Recent real-world data on the use and continuation of antipsychotic therapy in PD are lacking. The objectives of this study are to (1) examine the continuation of overall and initial antipsychotic therapy in individuals with PD and (2) determine whether continuation varies by drug dopamine receptor blocking activity. Methods: We conducted a retrospective cohort study using U.S. commercially insured individuals in Optum 2001– 2019. Adults aged 40 years or older with PD initiating antipsychotic therapy, with continuous insurance coverage for at least 6 months following drug initiation, were included. Exposure to pimavanserin, quetiapine, clozapine, aripiprazole, risperidone, or olanzapine was identified based on pharmacy claims. Six-month continuation of overall and initial antipsychotic therapy was estimated by time to complete discontinuation or switching to a different antipsychotic. Cox proportional hazards models evaluated factors associated with discontinuation. Results: Overall, 38.6% of 3566 PD patients in our sample discontinued antipsychotic therapy after the first prescription, 61.4% continued with overall treatment within 6 months of initiation. Clozapine use was too rare to include in statistical analyses.
    [Show full text]
  • A Phase 3, Multicenter, Randomized, Double-Blind
    Official Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment NCT Number: NCT03999918 Document Date: 21 Jun 2020 CLINICAL STUDY PROTOCOL UNMASKED PROTOCOL A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment Protocol Number: ACP-103-054 Amendment 4 EudraCT Number: 2018-003251-37 Original Protocol Date: 30 August 2018 Protocol Amendment 1 Date: 05 December 2018 Protocol Amendment 2 Date: 18 March 2019 Protocol Amendment 3 Date: 29 October 2019 Protocol Amendment 4 Date: 21 June 2020 Confidentiality Statement This protocol is the confidential information of ACADIA Pharmaceuticals Inc. and is intended solely for the guidance of the clinical investigation. This protocol may not be disclosed to parties not associated with the clinical investigation or used for any purpose without the prior written consent of ACADIA Pharmaceuticals Inc. Confidential and Proprietary Information of ACADIA Pharmaceuticals Inc. Page 1 of 81 Study: ACP-103-054 Final Version: 1.0 Clinical Study Protocol Amendment 4 UNMASKED VERSION Date: 21 June 2020 SPONSOR SIGNATURE PAGE Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment ACADIA President: President ACADIA Pharmaceuticals Inc. See appended electronic signature page Signature Date ACADIA Study Lead: Executive Director, Clinical Research ACADIA Pharmaceuticals Inc.
    [Show full text]
  • Emerging Anti-Insomnia Drugs: Tackling Sleeplessness and the Quality of Wake Time
    REVIEWS Emerging anti-insomnia drugs: tackling sleeplessness and the quality of wake time Keith A. Wafford* and Bjarke Ebert‡ Abstract | Sleep is essential for our physical and mental well being. However, when novel hypnotic drugs are developed, the focus tends to be on the marginal and statistically significant increase in minutes slept during the night instead of the effects on the quality of wakefulness. Recent research on the mechanisms underlying sleep and the control of the sleep–wake cycle has the potential to aid the development of novel hypnotic drugs; however, this potential has not yet been realized. Here, we review the current understanding of how hypnotic drugs act, and discuss how new, more effective drugs and treatment strategies for insomnia might be achieved by taking into consideration the daytime consequences of disrupted sleep. Primary insomnia Humans spend approximately one-third of their lifetime Insomnia is defined as difficulty in initiating and/or Patients who suffer from sleeping, but we still know relatively little about why this maintaining sleep. The incidence of insomnia in the gen- sleeplessness for at least process is so critical for every living animal. Current eral population is between 10–30%, and approximately 1 month that cannot be thinking suggests that waking activity is relatively 50% of the cases complain of serious daytime conse- attributed to a medical, dynamic in terms of using the body’s resources: breaking quences, such as inability to concentrate, reduced energy psychiatric or an environmental cause (such as drug abuse or down proteins, gathering information and expending and memory problems. When this persists for more medications).
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates Et Al
    US 20150.072964A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2015/0072964 A1 Mates et al. (43) Pub. Date: Mar. 12, 2015 (54) NOVELMETHODS filed on Apr. 14, 2012, provisional application No. 61/624.293, filed on Apr. 14, 2012, provisional appli (71) Applicant: INTRA-CELLULAR THERAPIES, cation No. 61/671,713, filed on Jul. 14, 2012, provi INC., New York, NY (US) sional application No. 61/671,723, filed on Jul. 14, 2012. (72) Inventors: Sharon Mates, New York, NY (US); Robert Davis, New York, NY (US); Publication Classification Kimberly Vanover, New York, NY (US); Lawrence Wennogle, New York, (51) Int. Cl. NY (US) C07D 47L/6 (2006.01) A613 L/4985 (2006.01) (21) Appl. No.: 14/394,469 A6II 45/06 (2006.01) (52) U.S. Cl. (22) PCT Fled: Apr. 14, 2013 CPC .............. C07D 471/16 (2013.01); A61K 45/06 (2013.01); A61 K3I/4985 (2013.01) (86) PCT NO.: PCT/US13A36512 USPC ...... 514/171; 514/250; 514/211.13: 514/217; S371 (c)(1), 514/214.02: 514/220 (2) Date: Oct. 14, 2014 (57) ABSTRACT Use of particular substituted heterocycle fused gamma-car Related U.S. Application Data boline compounds as pharmaceuticals for the treatment of (60) Provisional application No. 61/624.291, filed on Apr. agitation, aggressive behaviors, posttraumatic stress disorder 14, 2012, provisional application No. 61/624,292, or impulse control disorders. US 2015/0072964 A1 Mar. 12, 2015 NOVEL METHODS One type of ICD is Intermittent Explosive Disorder (IED) which involves violence or rage. There is a loss of control CROSS REFERENCE TO RELATED grossly out of proportion to any precipitating psychosocial APPLICATIONS stresses.
    [Show full text]
  • Pimavanserin: a Potentially Safer Alternative to Clozapine for Refractory Hallucinations and Delusions
    From the Editor Pimavanserin: A potentially safer alternative to clozapine for refractory hallucinations and delusions Up to 30% of patients with schizo- established a nonprofit foundation Henry A. Nasrallah, MD we called CURESZ (Comprehensive Editor-in-Chief phrenia do not respond to dopamine antagonists, which include all first- and Understanding via Research and Education in Schizophrenia), and assem- second-generation antipsychotics. bled a panel of 80 clozapine experts They are labeled as “treatment-resis- across the country to provide access to tant” if they have a partial response, clozapine for the hundreds of thousands Our clinical team or “treatment-refractory” if their hal- of individuals with refractory psychosis who never received a trial of clozapine made a serendipitous lucinations and/or delusions do not from their psychiatrists or psychiatric discovery about the improve at all despite multiple trials nurse practitioners. (Visit CURESZ.org efficacy of pimavanserin of antipsychotics. for details.) Bethany was very lucky to respond in patients with That’s why clozapine is considered and recover completely, because only schizophrenia who a “lifesaver” for such patients, a last- 40% of patients with refractory psycho- failed to respond to resort medication that unshackles sis respond to clozapine. She does not patients with refractory psychotic mind having her blood drawn every clozapine therapy symptoms from the tyranny of audi- week to measure her white blood cell tory and/or visual hallucinations and count for early detection of potentially the reality distortion of fixed false fatal agranulocytosis. Many refrac- beliefs such as paranoid delusions. tory, often homeless patients with Many long-suffering patients with chronic schizophrenia refuse to have refractory psychosis recover and return weekly phlebotomy and therefore are to their baseline, thanks to clozapine.
    [Show full text]
  • United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent: *May 26 , 2020
    US010660887B2 United States Patent (10 ) Patent No.: US 10,660,887 B2 Javitt (45 ) Date of Patent : *May 26 , 2020 (54 ) COMPOSITION AND METHOD FOR (56 ) References Cited TREATMENT OF DEPRESSION AND PSYCHOSIS IN HUMANS U.S. PATENT DOCUMENTS 6,228,875 B1 5/2001 Tsai et al. ( 71 ) Applicant : Glytech , LLC , Ft. Lee , NJ (US ) 2004/0157926 A1 * 8/2004 Heresco - Levy A61K 31/198 514/561 (72 ) Inventor: Daniel C. Javitt , Ft. Lee , NJ (US ) 2005/0261340 Al 11/2005 Weiner 2006/0204486 Al 9/2006 Pyke et al . 2008/0194631 Al 8/2008 Trovero et al. ( 73 ) Assignee : GLYTECH , LLC , Ft. Lee , NJ (US ) 2008/0194698 A1 8/2008 Hermanussen et al . 2010/0069399 A1 * 3/2010 Gant CO7D 401/12 ( * ) Notice : Subject to any disclaimer, the term of this 514 / 253.07 patent is extended or adjusted under 35 2010/0216805 Al 8/2010 Barlow 2011/0207776 Al 8/2011 Buntinx U.S.C. 154 ( b ) by 95 days . 2011/0237602 A1 9/2011 Meltzer This patent is subject to a terminal dis 2011/0306586 Al 12/2011 Khan claimer . 2012/0041026 A1 2/2012 Waizumi ( 21 ) Appl. No.: 15 /650,912 FOREIGN PATENT DOCUMENTS CN 101090721 12/2007 ( 22 ) Filed : Jul. 16 , 17 KR 2007 0017136 2/2007 WO 2005/065308 7/2005 (65 ) Prior Publication Data WO 2005/079756 9/2005 WO 2011044089 4/2011 US 2017/0312275 A1 Nov. 2 , 2017 WO 2012/104852 8/2012 WO 2005/000216 9/2013 WO 2013138322 9/2013 Related U.S. Application Data (63 ) Continuation of application No.
    [Show full text]
  • Antipsychotics
    bmchp.org | 888-566-0008 wellsense.org | 877-957-1300 Pharmacy Policy Antipsychotics Policy Number: 9.503 Version Number: 2.1 Version Effective Date: 9/1/2021 Product Applicability All Plan+ Products Well Sense Health Plan Boston Medical Center HealthNet Plan New Hampshire Medicaid MassHealth - MCO MassHealth - ACO Qualified Health Plans/ConnectorCare/Employer Choice Direct Senior Care Options __________________________________ Note: Disclaimer and audit information is located at the end of this document. Prior Authorization Policy Products Affected: aripiprazole ODT Latuda (lurasidone) aripiprazole Sol Nuplazid (pimavanserin) asenapine maleate Rexulti (brexpiprazole) clozapine ODT Vraylar (cariprazine) risperidone ODT Versacloz (clozapine) Fanapt (iloperidone) Secuado (asenapine) Paliperidone The Plan may authorize coverage of the above products for members meeting the following criteria: Covered All FDA approved indications not otherwise excluded Use All indications supported by established clinical literature for the medical condition and age + Plan refers to Boston Medical Center Health Plan, Inc. and its affiliates and subsidiaries offering health coverage plans to enrolled members. The Plan operates in Massachusetts under the trade name Boston Medical Center HealthNet Plan and in other states under the trade name Well Sense Health Plan. Antipsychotics 1 of 6 Exclusion None Criteria Required Medical Information clozapine ODT, risperidone ODT, aripiprazole ODT, aripiprazole sol, Versacloz 1. A diagnosis of bipolar disorder, schizophrenia, or other psychotic disorder; OR 2. A diagnosis of major depression requiring adjunct therapy ( aripiprazole ODT, aripiprazole sol only); AND 3. Clinical swallowing difficulties (including unwillingness to swallow tablets) Fanapt, palipedione (oral), Latuda, Vraylar 1. A diagnosis of bipolar disorder, schizophrenia, or other psychotic disorder; AND 2. An inadequate response, intolerance or contraindication to a trial of two covered atypical antipsychotics (See Appendix A) Nuplazid 1.
    [Show full text]
  • Copyright by Holly L. Chapman 2020
    Copyright by Holly L. Chapman 2020 EFFECTS OF VOLINANSERIN ON SLEEP AND WAKE STAGES AND THE EEG SPECTRUM DURING NICOTINE WITHDRAWAL IN RATS by Holly L. Chapman, B.S. THESIS Presented to the Faculty of The University of Houston-Clear Lake In Partial Fulfillment Of the Requirements For the Degree MASTER OF SCIENCE in Psychology THE UNIVERSITY OF HOUSTON-CLEAR LAKE MAY, 2020 EFFECTS OF VOLINANSERIN ON SLEEP AND WAKE STAGES AND THE EEG SPECTRUM DURING NICOTINE WITHDRAWAL IN RATS by Holly L. Chapman APPROVED BY __________________________________________ Christopher P. Ward, Ph.D., Chair __________________________________________ David H. Malin, Ph.D., Co-Chair RECEIVED/APPROVED BY THE COLLEGE OF HUMAN SCIENCES AND HUMANITIES: Samuel Gladden, Ph.D., Associate Dean __________________________________________ Rick Short, Ph.D., Dean Dedication To my family, whose unflinching support means the world to me and I hope one day I can return in kind. Acknowledgements To everyone else that believed, persisted, and achieved around me and gave me the strength to do the same. Special acknowledgements go out to my thesis committee Dr. Ward and Dr. Malin for having the patience to get this project off the ground, again, and make the most of our resources. Huge thanks to Joseph R. Campbell and Ping Sun Tsai for fast-tracking my motivation/sanity and digging into the science and reviewing my writing with me. v ABSTRACT EFFECTS OF VOLINANSERIN ON SLEEP AND WAKE STAGES AND THE EEG SPECTRUM DURING NICOTINE WITHDRAWAL IN RATS Holly L. Chapman University of Houston-Clear Lake, 2020 Thesis Chair: Dr. Christopher P. Ward Co-Chair: Dr.
    [Show full text]